These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8324873)

  • 1. Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey.
    Berg SL; Balis FM; McCully CL; Godwin KS; Poplack DG
    Cancer Chemother Pharmacol; 1993; 32(4):310-4. PubMed ID: 8324873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.
    Riccardi R; Holcenberg JS; Glaubiger DL; Wood JH; Poplack DG
    Cancer Res; 1981 Nov; 41(11 Pt 1):4554-8. PubMed ID: 6895481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
    Panetta JC; Liu Y; Bottiglieri T; Arning E; Cheng C; Karol SE; Yang JJ; Zhou Y; Inaba H; Pui CH; Jeha S; Relling MV
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):655-664. PubMed ID: 34170389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
    Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
    Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyethylene glycol-L-asparaginase and L-asparaginase studies in rabbits.
    Ho DH; Wang CY; Lin JR; Brown N; Newman RA; Krakoff IH
    Drug Metab Dispos; 1988; 16(1):27-9. PubMed ID: 2894951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL.
    Appel IM; Pinheiro JP; den Boer ML; Lanvers C; Reniers NC; Boos J; Pieters R
    Leukemia; 2003 Nov; 17(11):2254-6. PubMed ID: 14523472
    [No Abstract]   [Full Text] [Related]  

  • 8. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
    Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
    Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
    Woo MH; Hak LJ; Storm MC; Gajjar AJ; Sandlund JT; Harrison PL; Wang B; Pui CH; Relling MV
    J Clin Oncol; 1999 May; 17(5):1568-73. PubMed ID: 10334545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors.
    Taylor CW; Dorr RT; Fanta P; Hersh EM; Salmon SE
    Cancer Chemother Pharmacol; 2001; 47(1):83-8. PubMed ID: 11221967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
    Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
    Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
    Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
    Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
    J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
    Vieira Pinheiro JP; Müller HJ; Schwabe D; Gunkel M; Casimiro da Palma J; Henze G; von Schütz V; Winkelhorst M; Würthwein G; Boos J
    Br J Haematol; 2001 Apr; 113(1):115-9. PubMed ID: 11328290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct.
    Park YK; Abuchowski A; Davis S; Davis F
    Anticancer Res; 1981; 1(6):373-6. PubMed ID: 7046623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
    Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
    Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
    Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH
    Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.
    Panetta JC; Gajjar A; Hijiya N; Hak LJ; Cheng C; Liu W; Pui CH; Relling MV
    Clin Pharmacol Ther; 2009 Dec; 86(6):651-8. PubMed ID: 19741605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations.
    Ballerini A; Moro F; Nerini IF; Marzo CM; Di Clemente A; Ferrari M; D'Incalci M; Biondi A; Colombini A; Conter V; Porcu L; Cervo L; Rizzari C; Zucchetti M
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1267-1271. PubMed ID: 28424964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEG-asparaginase.
    Fu CH; Sakamoto KM
    Expert Opin Pharmacother; 2007 Aug; 8(12):1977-84. PubMed ID: 17696798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.